METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Clinical trials for METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for head and neck cancer: Three-Drug showdown after immunotherapy fails
Disease control OngoingThis study compares three different drug combinations for people with head and neck cancer that has spread or returned after immunotherapy stopped working. About 430 adults will receive either standard chemo plus cetuximab, chemo plus bevacizumab, or a combination of atezolizumab…
Matched conditions: METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 02:20 UTC
-
Promising combo aims to shrink tough head and neck cancers
Disease control OngoingThis study tests whether adding an immunotherapy drug (cemiplimab) to low-dose chemotherapy can shrink tumors in people with head and neck cancer that has returned or spread. About 46 adults who have not had prior treatment for advanced disease will receive the combination. The m…
Matched conditions: METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Marcelo Bonomi • Aim: Disease control
Last updated May 17, 2026 02:18 UTC
-
New drug combo shows promise for tough head and neck cancer
Disease control OngoingThis study tests whether adding ramucirumab to pembrolizumab works better than pembrolizumab alone for people with advanced head and neck cancer that has come back or spread. About 37 adults with PD-L1 positive cancer will take part. The goal is to see if the combination shrinks …
Matched conditions: METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated May 17, 2026 02:03 UTC
-
New combo aims to boost immunotherapy for head and neck cancer
Disease control OngoingThis study tests whether adding the drug ipatasertib to standard immunotherapy (pembrolizumab) helps people with head and neck cancer that has returned or spread. About 52 adults with incurable, measurable disease will receive either the combo or pembrolizumab alone. The goal is …
Matched conditions: METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 02:03 UTC
-
Radiation boost may improve immunotherapy for advanced head and neck cancer
Disease control OngoingThis study compares two treatments for head and neck cancer that has spread to other parts of the body. All participants receive the immunotherapy drug pembrolizumab plus chemotherapy. Half also get targeted radiation to their tumors. The goal is to see if adding radiation helps …
Matched conditions: METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New combo offers hope for head and neck cancer that resists immunotherapy
Disease control OngoingThis study tested a combination of two drugs—nab-paclitaxel (a chemotherapy) and nivolumab (an immunotherapy)—in 46 adults with advanced head and neck cancer that had stopped responding to a prior immunotherapy. The goal was to see if the combo could shrink tumors or slow disease…
Matched conditions: METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated May 12, 2026 13:41 UTC
-
New combo therapy targets Hard-to-Treat head and neck cancers
Disease control OngoingThis study tests whether adding the drug sorafenib to standard chemotherapy (carboplatin and paclitaxel) can help control advanced head and neck cancer that has spread or returned. About 48 adults with this type of cancer will receive the combination treatment. The goal is to see…
Matched conditions: METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 08, 2026 12:00 UTC
-
Two-Drug combo shows promise in Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a combination of two drugs—sonidegib and pembrolizumab—in people with advanced solid tumors that have spread. The goal is to find the safest dose of sonidegib when used with pembrolizumab and to see if the pair can shrink tumors. About 36 adults with …
Matched conditions: METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 08, 2026 12:00 UTC
-
Double immune attack: new combo therapy targets Hard-to-Treat head and neck cancers
Disease control OngoingThis study tested a combination of two drugs—cetuximab and interleukin-12—in 23 people with head and neck cancer that had spread, returned, or could not be surgically removed. The goal was to find the safest dose of interleukin-12 when given with cetuximab and to see if the pair …
Matched conditions: METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 04, 2026 16:31 UTC
-
New triple-drug combo aims to shrink advanced head and neck tumors
Disease control OngoingThis study tests a three-drug combination (olaparib, pembrolizumab, and carboplatin) as a first treatment for people with head and neck cancer that has come back or spread. The goal is to see if this mix shrinks tumors better than the current standard therapy. About 30 adults wit…
Matched conditions: METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated May 04, 2026 16:23 UTC
-
Fasting to fight cancer: study tests eating windows for better immunotherapy results
Knowledge-focused TerminatedThis study aimed to see if limiting eating to a 10-hour window each day could improve how well immunotherapy works in people with advanced head and neck or kidney cancer. Researchers wanted to know if this eating pattern changes gut bacteria and boosts treatment response. The stu…
Matched conditions: METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: Duke University • Aim: Knowledge-focused
Last updated May 17, 2026 02:05 UTC